Waning immunity against mumps in vaccinated young adults, France 2013

Waning immunity against mumps in vaccinated young adults, France 2013
复制标题

DOI:
10.2807/1560-7917.es.2016.21.10.30156
复制
发表时间:
2016-03-10
期刊:
影响因子:
19
通讯作者:
Rolland, P.
Rolland, P.
中科院分区:
医学2区
文献类型:
--
作者:
Vygen, S.;Fischer, A.;Rolland, P.

文献摘要

被引文献

相似文献

2013年,法国通报了15起流行性腮腺炎病例;72%(82/114)的病例接种了两次麻疹-流行性腮腺炎-风疹疫苗。为了确定自上次接种以来腮腺炎的风险是否随着时间的推移而增加,我们在大学和军营的集群中进行了一项病例对照研究。2013年,一名确诊病例出现唾液腺发炎,并经实验室确诊。2013年出现的一例唾液腺发炎或持续2天或与确诊病例有流行病学联系的疑似病例。对照组没有腮腺炎症状,参加了相同的大学课程、学生派对或军营。我们通过网络问卷和病历收集临床和疫苗接种数据。我们使用Logistic回归计算调整后的优势比(AOR)。59%(50/85)的病例和62%(199/321)的对照组接种过两次疫苗。自第二次接种以来,接种两次疫苗的个体患腮腺炎的几率每过一年就增加10%(AOR 1.10;95%可信区间:1.02-1.19;p=0.02)。自接种以来,腮腺炎免疫力随着接种时间的延长而减弱。我们的发现有助于法国公共卫生高级委员会决定在暴发期间向第二次接种日期为10年的个人推荐第三次MMR剂量。
In 2013, 15 clusters of mumps were notified in France; 72% (82/114) of the cases had been vaccinated twice with measles-mumps-rubella vaccine. To determine whether the risk of mumps increased with time since the last vaccination, we conducted a case-control study among clusters in universities and military barracks. A confirmed case had an inflammation of a salivary gland plus laboratory confirmation in 2013. A probable case presented with inflammation of a salivary gland in 2013 either lasting for > 2 days or with epidemiological link to a confirmed case. Controls had no mumps symptoms and attended the same university course, student party or military barracks. We collected clinical and vaccination data via web questionnaire and medical records. We calculated adjusted odds ratios (aOR) using logistic regression. 59% (50/85) of cases and 62% (199/321) of controls had been vaccinated twice. The odds of mumps increased for twice-vaccinated individuals by 10% for every year that had passed since the second dose (aOR 1.10; 95% confidence interval (CI): 1.02-1.19; p = 0.02). Mumps immunity waned with increasing time since vaccination. Our findings contributed to the French High Council of Public Health's decision to recommend a third MMR dose during outbreaks for individuals whose second dose dates > 10 years.